Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 1/2015

01-01-2015 | Breast Oncology

Breast Conservation in the Setting of Contemporary Multimodality Treatment Provides Excellent Outcomes for Patients with Occult Primary Breast Cancer

Authors: Natasha M. Rueth, MD, MS, Dalliah M. Black, MD, Angela R. Limmer, MS, PA, Emmanuel Gabriel, MD, PhD, Lei Huo, MD, Bruno D. Fornage, MD, Basak E. Dogan, MD, Mariana Chavez-MacGregor, MD, MS, Min Yi, MD, PhD, Kelly K. Hunt, MD, Eric A. Strom, MD

Published in: Annals of Surgical Oncology | Issue 1/2015

Login to get access

Abstract

Purpose

To evaluate recurrence and survival for patients with occult (T0N+) breast cancer who underwent contemporary treatment, assessing outcomes for breast conservation and mastectomy.

Methods

We performed a single-institution review of women with occult breast cancer presenting with axillary metastasis without identifiable breast tumor or distant metastasis. We excluded patients with tumors in the axillary tail or mastectomy specimen, patients with additional nonbreast cancer diagnoses, and patients with a history of breast cancer. Breast conservation was defined as axillary node dissection with radiation therapy, without breast surgery. We evaluated patient, tumor, treatment, and outcome variables. Patients were assessed for local, regional, and distant recurrences. Overall survival was calculated using the Kaplan–Meier method.

Results

Thirty-six patients met criteria for occult breast cancer. Most of these patients (77.8 %) had N1 disease. Fifty percent of cancers (n = 18) were estrogen receptor–positive; 12 (33.3 %) were triple-negative. All patients were evaluated with mammography. Thirty-five patients had breast ultrasound (97.2 %) and 33 (91.7 %) had an MRI. Thirty-four patients (94.4 %) were treated with chemotherapy and 33 (91.7 %) with radiotherapy. Twenty-seven patients (75.0 %) were treated with breast conservation. The median follow-up was 64 months. There were no local or regional failures. One distant recurrence occurred >5 years after diagnosis, resulting in a 5-years overall survival rate of 100 %. There were no significant survival differences between patients receiving breast conservation versus mastectomy (p = 0.7).

Conclusions

Breast conservation—performed with contemporary imaging and multimodality treatment—provides excellent local control and survival for women with T0N+ breast cancer and can be safely offered instead of mastectomy.
Literature
1.
Baron PL, Moore MP, Kinne DW, et al. Occult breast cancer presenting with axillary metastases. Updated management. Arch Surg. 1990;125:210–4.CrossRef
2.
Kemeny MM, Rivera DE, Terz JJ, Benfield JR. Occult primary adenocarcinoma with axillary metastases. Am J Surg. 1986;152:43–7.PubMedCrossRef
3.
4.
Rosen PP, Kimmel M. Occult breast carcinoma presenting with axillary lymph node metastases: a follow-up study of 48 patients. Hum Pathol. 1990;21:518–23.PubMedCrossRef
5.
6.
Khandelwal AK, Garguilo GA. Therapeutic options for occult breast cancer: a survey of the American Society of Breast Surgeons and review of the literature. Am J Surg. 2005;190:609–13.PubMedCrossRef
7.
Lanitis S, Behranwala KA, Al-Mufti R, Hadjiminas D. Axillary metastatic disease as presentation of occult or contralateral breast cancer. Breast. 2009;18:225–7.PubMedCrossRef
8.
Walker GV, Smith GL, Perkins GH, et al. Population-based analysis of occult primary breast cancer with axillary lymph node metastasis. Cancer. 2010;116:4000–6.PubMedCrossRef
9.
10.
Ellerbroek N, Holmes F, Singletary E, et al. Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin. Cancer. 1990;66:1461–7.PubMedCrossRef
11.
Merson M, Andreola S, Galimberti V, et al. Breast carcinoma presenting as axillary metastases without evidence of a primary tumor. Cancer. 1992;70:504–8.PubMedCrossRef
12.
Valero V, Buzdar AU, McNeese M, et al. Primary chemotherapy in the treatment of breast cancer: the University of Texas M. D. Anderson Cancer Center experience. Clin Breast Cancer. 2002;3 Suppl 2:S63–8.PubMedCrossRef
13.
Cance WG, Carey LA, Calvo BF, et al. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival. Ann Surg. 2002;236:295–302; discussion 293–302.
14.
Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.PubMedCrossRef
15.
Brill KL, Brenin DR. Occult breast cancer and axillary mass. Curr Treat Options Oncol. 2001;2:149–55.PubMedCrossRef
16.
Foroudi F, Tiver KW. Occult breast carcinoma presenting as axillary metastases. Int J Radiat Oncol Biol Phys. 2000;47:143–7.PubMedCrossRef
17.
Shannon C, Walsh G, Sapunar F, et al. Occult primary breast carcinoma presenting as axillary lymphadenopathy. Breast. 2002;11:414–8.PubMedCrossRef
18.
Vlastos G, Jean ME, Mirza AN et al. Feasibility of breast preservation in the treatment of occult primary carcinoma presenting with axillary metastases. Ann Surg Oncol. 2001;8:425–431.PubMedCrossRef
19.
Fowble B, Gray R, Gilchrist K, et al. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 1988;6:1107–17.PubMed
20.
Whillis D, Brown PW, Rodger A. Adenocarcinoma from an unknown primary presenting in women with an axillary mass. Clin Oncol (R Coll Radiol). 1990;2:189–92.PubMedCrossRef
21.
Buchanan CL, Morris EA, Dorn PL, et al. Utility of breast magnetic resonance imaging in patients with occult primary breast cancer. Ann Surg Oncol. 2005;12:1045–53.PubMedCrossRef
22.
Chen C, Orel SG, Harris E, et al. Outcome after treatment of patients with mammographically occult, magnetic resonance imaging-detected breast cancer presenting with axillary lymphadenopathy. Clin Breast Cancer. 2004;5:72–7.PubMedCrossRef
23.
McMahon K, Medoro L, Kennedy D. Breast magnetic resonance imaging: an essential role in malignant axillary lymphadenopathy of unknown origin. Australas Radiol. 2005;49:382–9.PubMedCrossRef
24.
Morris EA, Schwartz LH, Dershaw DD et al. MR imaging of the breast in patients with occult primary breast carcinoma. Radiology. 1997;205:437–40.PubMedCrossRef
25.
Obdeijn IM, Brouwers-Kuyper EM, Tilanus-Linthorst MM, et al. MR imaging-guided sonography followed by fine-needle aspiration cytology in occult carcinoma of the breast. AJR Am J Roentgenol. 2000;174:1079–84.PubMedCrossRef
26.
Olson JA Jr., Morris EA, Van Zee KJ et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol. 2000;7:411–5.PubMedCrossRef
27.
Orel SG, Weinstein SP, Schnall MD et al. Breast MR imaging in patients with axillary node metastases and unknown primary malignancy. Radiology. 1999;212:543–9.PubMedCrossRef
28.
Vilcoq JR, Calle R, Ferme F, Veith F. Conservative treatment of axillary adenopathy due to probable subclinical breast cancer. Arch Surg. 1982;117:1136–8.PubMedCrossRef
Metadata
Title
Breast Conservation in the Setting of Contemporary Multimodality Treatment Provides Excellent Outcomes for Patients with Occult Primary Breast Cancer
Authors
Natasha M. Rueth, MD, MS
Dalliah M. Black, MD
Angela R. Limmer, MS, PA
Emmanuel Gabriel, MD, PhD
Lei Huo, MD
Bruno D. Fornage, MD
Basak E. Dogan, MD
Mariana Chavez-MacGregor, MD, MS
Min Yi, MD, PhD
Kelly K. Hunt, MD
Eric A. Strom, MD
Publication date
01-01-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 1/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3991-0

Other articles of this Issue 1/2015

Annals of Surgical Oncology 1/2015 Go to the issue

Endocrine Tumors

Clinicopathologic Characteristics of Incidentally Identified Pheochromocytoma

Breast Oncology

Clinical and Pathological Response to Neoadjuvant Chemotherapy Based on Primary Tumor Reduction is Correlated to Survival in Hormone Receptor-Positive but not Hormone Receptor-Negative Locally Advanced Breast Cancer

Endocrine Tumors

Factors Associated with Higher Risk of Complications After Adrenal Surgery

Bone and Soft Tissue Sarcomas

Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach From the Trans-Atlantic RPS Working Group

Melanomas

Deep Lymph Node Metastases in the Groin Significantly Affects Prognosis, Particularly in Sentinel Node-Positive Melanoma Patients

Healthcare Policy and Outcomes

Incorporating Surgical Quality into the AJCC 7th Edition Improves Staging Accuracy in Gastric Cancer